Drug combo for melanoma that spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma that started in the skin (cutaneous) and has spread to your brain.
- Your tumor has a specific genetic change (RAS, BRAF, or NF1 mutation, or is 'triple wildtype').
- You have at least one brain tumor that hasn't been treated with surgery or radiation, and it's between 0.5 cm and 4 cm in size.
- You have already tried at least one type of immunotherapy for your melanoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
This Phase 2 trial studies how giving steroid medicine for brain swelling may help people with melanoma that has spread to the brain, and whether adding a targeted approach works for a specific genetic tumor type. It may help shrink brain tumors and improve symptoms, while comparing how patients respond.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.